PMCTPharmaCountry
    Startseite
Studien & Berichte30. Aug. 2026•1 Min. Lesezeit

AI in Pharma Faces Data‑Gathering Delays, Not Scientific Limits

Vom PharmaCountry-Team

A recent note says most of the two‑week deviation investigation time is spent on data collection, not science, highlighting a bottleneck for AI tools in pharma.

Most of those two weeks is not science. It is finding and assembling the data, which is also where most of the AI sold to pharma quietly stalls.

Zusammengestellt vom PharmaCountry-Team · Quelle: FiercePharma

Themen:#AI#pharma#data management#deviation investigation#regulatory compliance

Weitere Artikel

Alle Einblicke anzeigen
Studien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische Updates
Korea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
Analyse
Pharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026